Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many infection/TB cautions are supported by the provided label sections (5.1, 5.3). However, several claims about specific adverse reactions (e.g., injection-site reactions and diarrhea/upper respiratory symptoms) and mechanistic explanations are not supported by the provided label excerpts, and some wording is more expansive than the label.
Category Scores
Accurate Statements
Cosentyx can increase the risk of infections.
5.1 Infections: "COSENTYX may increase the risk of infections."
The most commonly reported side effects of Cosentyx include infections.
6 Adverse Reactions cross-references infections as a discussed adverse reaction ("Infections" in list with [see Warnings and Precautions (5.1)]). (No explicit "most common" rate statement present in provided excerpt.)
Patients are advised to seek medical care promptly for signs of serious infection while taking Cosentyx.
5.1: "Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur."
Signs of serious infection include fever, worsening cough, and shortness of breath.
Not supported in the provided excerpts (5.1, 5.3, 6, 7).
Extra caution is needed for people with a history of recurrent infections when using Cosentyx.
5.1: "Exercise caution... in patients with a chronic infection or a history of recurrent infection."
Extra caution is needed for people with active infections when using Cosentyx.
5.1: "Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection."
Because immune modulation from Cosentyx can affect latent infections, clinicians typically screen for tuberculosis (TB) before starting biologic therapies like Cosentyx.
5.3: "Evaluate patients for active or latent TB infection prior to initiating treatment with COSENTYX." (The claim mentions biologic therapies generally and mechanistic rationale; label excerpt is specifically about Cosentyx and evaluation.)
People who develop symptoms that could indicate TB or other serious infections should get urgent evaluation.
5.3: "Monitor patients closely for signs and symptoms of active TB during and after treatment." AND 5.1: "Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur."
Injection-site reactions with Cosentyx can include redness, pain, swelling, or itching at the injection site.
Not supported in the provided excerpts (6 only lists adverse reaction categories and does not mention injection-site reactions).
Extra caution is needed for people with untreated latent TB when using Cosentyx.
5.3: "Initiate treatment of latent TB prior to administering COSENTYX." and "Evaluate patients for active or latent TB... prior to initiating."
Unsupported Statements
The most commonly reported side effects of Cosentyx include infections.
Provided label excerpts do not state "most commonly reported"; they only indicate infections are a discussed adverse reaction and give example infection rates in trials.
The most commonly reported side effects of Cosentyx include injection-site reactions such as rash or redness at the injection site.
Provided excerpts (5.1, 5.3, 6) do not mention injection-site reactions or rash/redness as injection-site events.
Cosentyx can cause injection-site reactions such as rash or redness at the injection site.
Injection-site reactions are not supported by the provided excerpts.
Cosentyx can cause diarrhea in some people.
Diarrhea is not mentioned in the provided label excerpts.
Cosentyx can cause upper respiratory symptoms in some people.
Although "upper respiratory tract infection" is discussed with example rates, the claim is framed as "upper respiratory symptoms" rather than infections; provided excerpt supports upper respiratory tract infections, not general symptom statements.
Signs of serious infection include fever, worsening cough, and shortness of breath.
No symptom examples (fever/cough/shortness of breath) are provided in the excerpts.
Because immune signaling, serious infections can be more likely.
The label excerpt supports increased infection risk but does not provide this specific immune-signaling mechanistic phrasing in the provided sections.
Cosentyx can increase susceptibility to infections by changing immune pathways.
The excerpts support increased infection risk but do not describe this mechanistic wording.
Cosentyx infection risk is especially relevant for people with a history of recurrent infections.
Recurrent infection caution is supported, but the claim adds "especially relevant" emphasis not explicitly present.
Cosentyx infection risk is especially relevant for people who are already on other immunosuppressive therapies.
The provided excerpts mention caution with chronic/recurrent infection and TB evaluation, but do not discuss immunosuppressive therapies as a specific risk factor.
Injection-site reactions with Cosentyx are typically mild.
No injection-site reaction severity information is present in the provided excerpts.
Patients should report persistent or severe skin reactions at the injection site to their clinician.
No instruction specific to injection-site skin reactions is present in the provided excerpts.
Discussing all other medicines that affect the immune system is important before starting Cosentyx.
The provided label excerpt for drug interactions addresses CYP450 substrate monitoring/adjustments; it does not state a general instruction to discuss all immune-modulating medicines.
Side effects generally reflect Cosentyx's overall mechanism, with infection risk and injection-related reactions being the main themes.
Provided excerpts support infection risk but do not support that injection-related reactions are a main theme, nor that side effects generally reflect the mechanism in this way.
Contradictions
Low
AI Statement
Cosentyx increases the risk of infections.
Label Reference
5.1 Infections: "COSENTYX may increase the risk of infections."
Important Omissions
TB precautions are more specific in the label: avoid administration in active TB, initiate latent TB treatment prior to dosing, consider anti-TB therapy when adequate confirmation/course cannot be confirmed, and consult a hepatitis specialist / not recommended in active viral hepatitis.
Importance:
Moderate
The label includes postmarketing reports of opportunistic infections and Hepatitis B virus reactivation; the claims provided do not mention HBV risk or the recommendation that COSENTYX is not recommended for active viral hepatitis.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant infection/TB evaluation and seek-care statements align with the label. However, additional unsupported specifics (e.g., injection-site reaction details and symptom examples for serious infection) could mislead or be incomplete. Omissions of HBV/viral hepatitis specifics and finer TB instructions could reduce label fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided label excerpts (especially injection-site reaction details, diarrhea, and specific symptom examples for serious infection). Some mechanistic and emphasis wording exceeds the excerpted label language.
Suggested Improvement
Restrict statements to what is supported in 5.1 and 5.3 (increased infection risk; caution with chronic/recurrent infection; seek medical advice for infection signs/symptoms; evaluate for active/latent TB; avoid in active TB; initiate latent TB treatment; monitor for active TB). If discussing adverse reactions beyond infections/TB, use only those adverse-reaction categories/details present in the full label.